Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Colorcon
Fuji
Cantor Fitzgerald
Fish and Richardson
Merck
Citi
Accenture
Cerilliant
Boehringer Ingelheim

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,320,716

« Back to Dashboard

Which drugs does patent 9,320,716 protect, and when does it expire?

Patent 9,320,716 protects UCERIS and is included in one NDA.

This patent has twenty-four patent family members in seventeen countries.
Summary for Patent: 9,320,716
Title:Controlled release and taste masking oral pharmaceutical compositions
Abstract: The invention relates to an oral pharmaceutical composition comprising an active agent, a macroscopically homogeneous structure and a gastro-resistant coating. The macroscopically homogeneous structure comprises at least one hydrophilic compound and at least one lipophilic compound and/or at least one amphiphilic compound. The macroscopically homogeneous structure controls the release of the active ingredient, and the gastro-resistant film prevents release of the active agent in the stomach.
Inventor(s): Villa; Roberto (Lecco, IT), Pedrani; Massimo (Gignese, IT), Ajani; Mauro (Milan, IT), Fossati; Lorenzo (Milan, IT)
Assignee: COSMO TECHNOLOGIES LIMITED (Dublin, IE)
Application Number:14/308,279
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 9,320,716

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms Intl UCERIS budesonide TABLET, EXTENDED RELEASE;ORAL 203634-001 Jan 14, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,320,716

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
ItalyMI99A1317Jun 14, 1999
ItalyMI2000A0422Mar 3, 2000

Non-Orange Book US Patents Family Members for Patent 9,320,716

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,273 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
9,592,203 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
7,410,651 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
9,132,093 Controlled release and taste making oral pharmaceutical composition ➤ Subscribe
9,737,489 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
RE43799 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
7,410,652 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
8,784,888 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
8,029,823 Controlled release and taste masking oral pharmaceutical composition ➤ Subscribe
7,431,943 Controlled release and taste masking oral pharmaceutical compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,320,716

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey 200200562 ➤ Subscribe
Germany 60005819 ➤ Subscribe
Denmark 1183014 ➤ Subscribe
European Patent Office 1183014 ➤ Subscribe
Spain 2208349 ➤ Subscribe
Hong Kong 1046244 ➤ Subscribe
Italy MI20000422 ➤ Subscribe
Italy 1317871 ➤ Subscribe
Italy MI991317 ➤ Subscribe
Japan 2003501457 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Covington
Boehringer Ingelheim
US Department of Justice
Express Scripts
Teva
Colorcon
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot